A Phase 2 interventional study of Cohort A: ORMD-0801 and Placebo oral capsule in T2DM (Type 2 Diabetes Mellitus), sponsored by Oramed, Ltd.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-11-08.
Sponsored by Oramed, Ltd. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 3,304 studies in Diabetes Mellitus, Type 2 with a site in United States — 343 open to participants now, 478 under way, 51 of them phase 3. Diabetes Mellitus, Type 2 · United States.
Among the 3,304 studies in Diabetes Mellitus, Type 2 with a site in United States, this one is the 621st largest by enrollment of the 2,957 interventional ones that give a count, is one of 126 that started in 2018, is one of 391 in phase 2, and was the 2,063rd registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →343 of the 3,304 studies in Diabetes Mellitus, Type 2 with a site in United States are open now. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in United States, Puerto Rico
Ages 18+
University of Minnesota · Sites in United States
Ages 30–75
Pfizer · Sites in United States
Ages 18+
Rahul Sachdeva · Sites in United States
Ages 18+ · Healthy volunteers
Amgen · Sites in United States, Canada
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
3,304 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 423 · Phase 2 464 · Phase 3 613 · Phase 4 300
First in 1976; this study’s year is marked. 126 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 373 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 90 across the 2,957 interventional studies, 128 across the 336 observational. Of the 2,648 that completed or were terminated, 1,165 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
1,486 of 3,304 have an industry lead sponsor. The 10 most frequent:
Oramed, Ltd. is the lead sponsor of 13 studies on the registry; 1 is open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 6 (75%) have results posted.
Oramed, Ltd. has 9 studies filed under Diabetes Mellitus, Type 2 — fewer than ten, so there is no comparison to draw.
187 of the studies in Diabetes Mellitus, Type 2 with a site in United States that are under way reach primary completion within a year, 8 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06858878Phase 3AmgenEfficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT06731075Phase 3Oramed, Ltd.A Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus. | 2027-04-25 |
| NCT07220759Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide | 2027-05-12 |
| NCT07817251Phase 3Novo Nordisk A/SResearch Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema | 2027-06-09 |
| NCT06993792Phase 3Eli Lilly and CompanyA Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes | 2027-08 |
Add all 187 to your calendar (.ics) → With an account.
Among the 3,304 studies in Diabetes Mellitus, Type 2 with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a four-way (Participant, Care Provider, Investigator, Outcomes Assessor) masked (blinded) study designed to explore the efficacy of ORMD-0801 when given in different regimens across a dose range for up to 12 weeks in subjects with type 2 diabetes mellitus (T2DM).
This study is designed to explore the efficacy of ORMD-0801 when given in different regimens across a dose range for up to 12 weeks in subjects with type 2 diabetes mellitus (T2DM). There are two cohorts in this study. Approximately 360 subjects with T2DM will initially undergo a 2-week, single-blind placebo run-in period (Visits 1 and 2), followed by a 12-week treatment period (Visits 3 through 9). Cohort A will enroll 285 subjects; Cohort B will enroll 75 subjects
For 265 of the 285 subjects of Cohort A, the total 12-week treatment period will include a Part 1"dose escalation" interval (2 weeks, Visits 3 and 4) and a Part 2 stable dose "maintenance" interval (10 weeks, Visits 5 through 9).
In addition, per FDA request, the remaining 20 subjects (of the cohort total of 285 enrolled subjects) will receive excipient-matched placebo in a non-randomized single-blind fashion, TID (3 times per day), according to the same schedule as described above.
For Cohort B (75 of the 360 total subjects), the total 12-week treatment period will include a stable dosing period for both Part 1 (2 weeks, Visits 3 and 4) and Part 2 (10 weeks, Visits 5 through 9).
Cohort A data will be analyzed after Cohort A data collection has been completed (last subject for Cohort A screened on 7 May 2019). Estimated completion for Cohort A is October 2019. Cohort B data will be analyzed following the release of results from Cohort A.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Subjects with insulin-dependent diabetes
Subjects with the following secondary complications of diabetes:
Laboratory abnormalities at Screening include:
Use of the following medications:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dosed in the evening prior to bedtime (@ 10 PM ± 90 minutes)
Drug: Cohort A: ORMD-0801
Dosed in the evening prior to bedtime (@ 10 PM ± 90 minutes) and 30-45 minutes prior to breakfast.
Drug: Cohort A: ORMD-0801
ORMD-0801 three times daily - TID: dosed in the evening prior to bedtime (@ 10 PM ± 90 minutes) and 30-45 minutes prior to breakfast and lunch.
Drug: Cohort A: ORMD-0801
Placebo matched to one of the three active comparator arms. (either QHS, BID, or TID)
Drug: Placebo oral capsule
Excipient matched placebo in a non-randomized single-blind fashion, TID, dosed in the evening prior to bedtime (@ 10 PM ± 90 minutes) and 30-45 minutes prior to breakfast and lunch. This is an exploratory arm, per FDA. The results of this arm are not included in the primary analysis.
Drug: Placebo oral capsule
ORMD-0801 8 mg once daily - QHS: dosed in the evening prior to bedtime (@ 10 PM ± 90 minutes)
Drug: Cohort B: ORMD-0801
ORMD-0801 8 mg twice daily - BID: dosed in the evening prior to bedtime (@ 10 PM ± 90 minutes) and 30-45 minutes prior to breakfast.
Drug: Cohort B: ORMD-0801
ORMD-0801 16 mg once daily - QHS: dosed in the evening prior to bedtime (@ 10 PM ± 90 minutes)
Drug: Cohort B: ORMD-0801
ORMD-0801 16 mg twice daily - BID: dosed in the evening prior to bedtime (@ 10 PM ± 90 minutes) and 30-45 minutes prior to breakfast.
Drug: Cohort B: ORMD-0801
Cohort B - Matched Placebo Oral Capsule: dosed in the evening prior to bedtime (@ 10 PM ± 90 minutes)
Drug: Placebo oral capsule
Part 1 In the first two weeks of active treatment (Part 1) subjects will receive double-blind therapy according to their randomized regimen (placebo or ORMD-0801) to be taken QHS, BID or TID. Subjects will undergo a step-wise dose escalation from a starting dose of 16 mg (Visit 3), to 24 mg (Visit 4), to a top dose of 32 mg (Visit 5 onward). Subjects will then enter Part 2. Part 2: During Part 2, subjects will remain on fixed doses of ORMD-0801 (or matched placebo) for 10 weeks. Doses will not be adjusted unless clinically indicated for adverse events or hypoglycemia.
Also known as: Oral Insulin
Placebo provided QHS, BID, TID
Also known as: SBTI, disodium EDTA, fish oil, aerosil, and TWEEN 80.
Part 1 In the first two weeks of active treatment, subjects will receive double-blind therapy according to their randomized regimen (ORMD 0801 8 mg or 16 mg, or matched placebo) to be taken QHS or BID. Subjects will then enter Part 2 at the same dose and regimen administered in Part 1. Part 2 Subjects will remain on fixed doses of ORMD-0801 (or matched placebo) for 10 weeks. Doses will not be adjusted unless clinically indicated for adverse events or hypoglycemia.
Also known as: Oral Insulin
Change From Baseline of HbA1C (Glycated Hemoglobin)
Least Squares Means change in HbA1C from baseline to Week 12 of the treatment period, where HbA1C is reported in units of percent. The change in HbA1c from baseline to Week 12 is expressed as a change in the value of HbA1C.
Time frame: baseline (Run-in period, Week 0, Visit 1) and Week 12 (follow-up)
Mean Change From Baseline Over Time for HbA1C
Mean change from baseline (Run-In, Week 0 Visit 1) to Part 1, Visit 3 for HbA1C (measured in mmols/mol)
Time frame: Baseline (Run-In:Week 0, Visit 1) to Part 1, Visit 3, elapsed time: 3 weeks.
Change Over Time in Hb1Ac
Change of Hb1Ac from Baseline to Week 10, measured in mmol/mol
Time frame: Baseline (week 0, visit 1) to Week 10, part 2
Patients were recruited into two primary Cohorts, A and B. Cohort A: 1. ORMD-0801 1X daily 2. ORMD-0801 2X daily 3. ORMD-0801 3X daily 4. Matched Placebo Sub-Cohort A 20 subjects Per FDA, excipient matched placebo; randomized single-blind, TID, same schedule as for Cohort A. Not part of primary analysis. Cohort B: 1. ORMD-0801 8 mg 1X daily 2. ORMD-0801 8 mg 2X daily 3. ORMD-0801 16 mg 1X daily 4. ORMD-0801 16 mg 2X daily 5. Excipient matched placebo once daily
| Milestone | Cohort A: ORMD-0801 Once Daily - QHS | Cohort A: ORMD-0801 Twice Daily - BID | Cohort A: ORMD-0801 Three Times Daily - TID | Cohort A: Matched Placebo Oral Capsule | Cohort A (Sub-Cohort A): Excipient-Matched Placebo Three Times Daily-TID | Cohort B:ORMD-0801, 8 mg Once Daily - QHS: | Cohort B: ORMD-0801 8 mg Twice Daily - BID | Cohort B: ORMD-0801 16 mg Once Daily - QHS: | Cohort B: ORMD-0801 16 mg Twice Daily - BID | Cohort B - Matched Placebo Oral Capsule |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 69 | 68 | 69 | 66 | 20 | 15 | 17 | 18 | 15 | 16 |
| Completed | 62 | 58 | 58 | 56 | 19 | 13 | 15 | 16 | 11 | 14 |
| Not completed | 7 | 10 | 11 | 10 | 1 | 2 | 2 | 2 | 4 | 2 |
Least Squares Means change in HbA1C from baseline to Week 12 of the treatment period, where HbA1C is reported in units of percent. The change in HbA1c from baseline to Week 12 is expressed as a change in the value of HbA1C.
| percent HbA1C | Combined Cohort A +Cohort B: Matched-Placebo Oral Capsule | Cohort A: ORMD-0801 Once Daily - QHS | Cohort A: ORMD-0801 Twice Daily - BID | Cohort A: ORMD-0801 Three Times Daily - TID | Cohort B:ORMD-0801, 8 mg Once Daily - QHS: | Cohort B: ORMD-0801 8 mg Twice Daily - BID | Cohort B: ORMD-0801 16 mg Once Daily - QHS: | Cohort B: ORMD-0801 16 mg Twice Daily - BID |
|---|---|---|---|---|---|---|---|---|
| Change From Baseline of HbA1C (Glycated Hemoglobin) | -0.13 (-0.86 to 0.59) | -0.60 (-1.37 to 0.16) | -0.59 (-1.32 to 0.14) | -0.51 (-1.27 to 0.25) | -0.95 (-1.87 to -0.03) | -0.95 (-1.84 to -0.07) | 0.12 (-0.80 to 1.04) | -0.50 (-1.47 to 0.48) |
Mean change from baseline (Run-In, Week 0 Visit 1) to Part 1, Visit 3 for HbA1C (measured in mmols/mol)
| mmol/mol | Combined Cohort A+Cohort B: Matched-Placebo Oral Capsule | Cohort A: ORMD-0801 Once Daily - QHS | Cohort A: ORMD-0801 Twice Daily - BID | Cohort A: ORMD-0801 Three Times Daily - TID | Cohort B:ORMD-0801, 8 mg Once Daily - QHS: | Cohort B: ORMD-0801 8 mg Twice Daily - BID | Cohort B: ORMD-0801 16 mg Once Daily - QHS: | Cohort B: ORMD-0801 16 mg Twice Daily - BID |
|---|---|---|---|---|---|---|---|---|
| Mean Change From Baseline Over Time for HbA1C | -2.12 (-4.40 to 0.16) | -2.56 (-4.94 to -0.19) | -1.95 (-4.21 to 0.30) | -2.91 (-5.25 to -0.57) | -3.26 (-6.13 to -0.39) | -5.51 (-8.30 to -2.73) | -2.06 (-4.94 to 0.82) | -1.87 (-4.72 to 0.98) |
Change of Hb1Ac from Baseline to Week 10, measured in mmol/mol
| mmol/mol | Cohort A+Cohort B: Combined Matched Placebo Oral Capsule | Cohort A: ORMD-0801 Once Daily - QD | Cohort A: ORMD-0801 Twice Daily - BID | Cohort A: ORMD-0801 Three Times Daily - TID | Cohort B:ORMD-0801, 8 mg Once Daily - QD | Cohort B: ORMD-0801 8 mg Twice Daily - BID | Cohort B: ORMD-0801 16 mg Once Daily - QD | Cohort B: ORMD-0801 16 mg Twice Daily - BID |
|---|---|---|---|---|---|---|---|---|
| Change Over Time in Hb1Ac | -1.27 (-8.88 to 6.35) | -5.95 (-14.05 to 2.16) | -4.95 (-12.62 to 2.73) | -6.16 (-14.22 to 1.90) | -10.34 (-20.01 to -0.68) | -10.71 (-20.02 to -1.40) | -0.25 (-9.94 to 9.44) | -4.66 (-14.61 to 5.28) |
Collected over Each subject was followed for a period of 12 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Combined Cohort A + Cohort B: Matched Placebo | 0/82 (0%) | 0/82 (0%) | 11/82 (13.4%) |
| Cohort A: ORMD-0801 Once Daily - QD | 0/69 (0%) | 5/69 (7.2%) | 19/69 (27.5%) |
| Cohort A: ORMD-0801 Twice Daily - BID | 0/68 (0%) | 0/68 (0%) | 6/68 (8.8%) |
| Cohort A: ORMD-0801 Three Times Daily - TID | 0/69 (0%) | 3/69 (4.3%) | 10/69 (14.5%) |
| Cohort B:ORMD-0801, 8 mg Once Daily - QD | 0/15 (0%) | 0/15 (0%) | 5/15 (33.3%) |
| Cohort B: ORMD-0801 8 mg Twice Daily - BID | 0/17 (0%) | 0/17 (0%) | 2/17 (11.8%) |
| Cohort B: ORMD-0801 16 mg Once Daily - QD | 0/18 (0%) | 0/18 (0%) | 1/18 (5.6%) |
| Cohort B: ORMD-0801 16 mg Twice Daily - BID | 0/15 (0%) | 1/15 (6.7%) | 2/15 (13.3%) |
| Excipient Matched Placebo -TID | 1/20 (5%) | 3/20 (15%) | 13/20 (65%) |
| Event | Combined Cohort A + Cohort B: Matched Placebo | Cohort A: ORMD-0801 Once Daily - QD | Cohort A: ORMD-0801 Twice Daily - BID | Cohort A: ORMD-0801 Three Times Daily - TID | Cohort B:ORMD-0801, 8 mg Once Daily - QD | Cohort B: ORMD-0801 8 mg Twice Daily - BID | Cohort B: ORMD-0801 16 mg Once Daily - QD | Cohort B: ORMD-0801 16 mg Twice Daily - BID | Excipient Matched Placebo -TID |
|---|---|---|---|---|---|---|---|---|---|
| Chest PainGeneral disorders | 0/82 | 0/69 | 0/68 | 1/69 | 0/15 | 0/17 | 0/18 | 1/15 | 0/20 |
| Acute Myocardial InfarctionCardiac disorders | 0/82 | 0/69 | 0/68 | 1/69 | 0/15 | 0/17 | 0/18 | 0/15 | 1/20 |
| Myocardial InfarctionCardiac disorders | 0/82 | 0/69 | 0/68 | 0/69 | 0/15 | 0/17 | 0/18 | 0/15 | 1/20 |
| DeathGeneral disorders | 0/82 | 0/69 | 0/68 | 0/69 | 0/15 | 0/17 | 0/18 | 0/15 | 1/20 |
| OsteomyelitisInfections and infestations | 0/82 | 0/69 | 0/68 | 0/69 | 0/15 | 0/17 | 0/18 | 0/15 | 1/20 |
| PneumoniaInfections and infestations | — | 0/69 | 0/68 | 0/69 | 0/15 | 0/17 | 0/18 | 0/15 | 1/20 |
| Atrial FibrillationCardiac disorders | 0/82 | 2/69 | 0/68 | 0/69 | 0/15 | 0/17 | 0/18 | 0/15 | 0/20 |
| Angina PectorisCardiac disorders | 0/82 | 1/69 | 0/68 | 0/69 | 0/15 | 0/17 | 0/18 | 0/15 | 0/20 |
| Coronary Artery DiseaseCardiac disorders | 0/82 | 0/69 | 0/68 | 1/69 | 0/15 | 0/17 | 0/18 | 0/15 | 0/20 |
| Supraventricular TachycardiaCardiac disorders | 0/82 | 1/69 | 0/68 | 0/69 | 0/15 | 0/17 | 0/18 | 0/15 | 0/20 |
| Event | Combined Cohort A + Cohort B: Matched Placebo | Cohort A: ORMD-0801 Once Daily - QD | Cohort A: ORMD-0801 Twice Daily - BID | Cohort A: ORMD-0801 Three Times Daily - TID | Cohort B:ORMD-0801, 8 mg Once Daily - QD | Cohort B: ORMD-0801 8 mg Twice Daily - BID | Cohort B: ORMD-0801 16 mg Once Daily - QD | Cohort B: ORMD-0801 16 mg Twice Daily - BID | Excipient Matched Placebo -TID |
|---|---|---|---|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 3/82 | 2/69 | 3/68 | 8/69 | 1/15 | 0/17 | 0/18 | 0/15 | 3/20 |
| Atrial FibrillationCardiac disorders | 0/82 | 3/69 | 1/68 | 0/69 | 0/15 | 0/17 | 0/18 | 0/15 | 2/20 |
| ConstipationGastrointestinal disorders | 0/82 | 1/69 | 0/68 | 0/69 | 1/15 | 0/17 | 0/18 | 0/15 | 0/20 |
| NauseaGastrointestinal disorders | 1/82 | 2/69 | 0/68 | 1/69 | 1/15 | 0/17 | 0/18 | 1/15 | 0/20 |
| HypersensitivityImmune system disorders | 0/82 | 0/69 | 0/68 | 0/69 | 1/15 | 0/17 | 0/18 | 0/15 | 0/20 |
| CystitisGastrointestinal disorders | 1/82 | 0/69 | 0/68 | 0/69 | 1/15 | 1/17 | 0/18 | 0/15 | 0/20 |
| DiverticulitisInfections and infestations | 0/82 | 0/69 | 0/68 | 0/69 | 0/15 | 0/17 | 0/18 | 1/15 | 0/20 |
| AnemiaBlood and lymphatic system disorders | 0/82 | 3/69 | 1/68 | 0/69 | 0/15 | 1/17 | 1/18 | 0/15 | 0/20 |
| Atrioventricular Block First DegreeCardiac disorders | 0/82 | 1/69 | 0/68 | 0/69 | 0/15 | 0/17 | 0/18 | 0/15 | 1/20 |
| PalpitationsCardiac disorders | 1/82 | 0/69 | 0/68 | 0/69 | 0/15 | 0/17 | 0/18 | 0/15 | 1/20 |
| Age, Continuous(years) | Cohort A+Cohort B Combined: Matched Oral Capsule Placebo | Cohort A: ORMD-0801 Once Daily - QD | Cohort A: ORMD-0801 Twice Daily - BID | Cohort A: ORMD-0801 Three Times Daily - TID | Cohort B:ORMD-0801, 8 mg Once Daily - QD | Cohort B: ORMD-0801 8 mg Twice Daily - BID | Cohort B: ORMD-0801 16 mg Once Daily - QD | Cohort B: ORMD-0801 16 mg Twice Daily - BID | Sub-Cohort A: Excipient Matched Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 55.92 ± 9.914 | 56.72 ± 10.766 | 55.68 ± 10.569 | 55.22 ± 11.663 | 53.66 ± 8.22 | 56.87 ± 9.132 | 54.98 ± 11.229 | 54.98 ± 11.785 | 64.08 ± 9.218 | 55.73 ± 10.544 |
| Sex: Female, Male(Participants) | Cohort A+Cohort B Combined: Matched Oral Capsule Placebo | Cohort A: ORMD-0801 Once Daily - QD | Cohort A: ORMD-0801 Twice Daily - BID | Cohort A: ORMD-0801 Three Times Daily - TID | Cohort B:ORMD-0801, 8 mg Once Daily - QD | Cohort B: ORMD-0801 8 mg Twice Daily - BID | Cohort B: ORMD-0801 16 mg Once Daily - QD | Cohort B: ORMD-0801 16 mg Twice Daily - BID | Sub-Cohort A: Excipient Matched Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Female | 33 | 27 | 23 | 29 | 5 | 7 | 7 | 4 | 8 | 143 |
| Male | 49 | 42 | 45 | 40 | 10 | 10 | 11 | 11 | 12 | 230 |
| Ethnicity (NIH/OMB)(Participants) | Cohort A+Cohort B Combined: Matched Oral Capsule Placebo | Cohort A: ORMD-0801 Once Daily - QD | Cohort A: ORMD-0801 Twice Daily - BID | Cohort A: ORMD-0801 Three Times Daily - TID | Cohort B:ORMD-0801, 8 mg Once Daily - QD | Cohort B: ORMD-0801 8 mg Twice Daily - BID | Cohort B: ORMD-0801 16 mg Once Daily - QD | Cohort B: ORMD-0801 16 mg Twice Daily - BID | Sub-Cohort A: Excipient Matched Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 48 | 36 | 37 | 36 | 9 | 8 | 9 | 8 | 0 | 191 |
| Not Hispanic or Latino | 33 | 32 | 29 | 33 | 6 | 6 | 9 | 6 | 20 | 174 |
| Unknown or Not Reported | 1 | 1 | 2 | 0 | 0 | 3 | 0 | 1 | 0 | 8 |
| Race (NIH/OMB)(Participants) | Cohort A+Cohort B Combined: Matched Oral Capsule Placebo | Cohort A: ORMD-0801 Once Daily - QD | Cohort A: ORMD-0801 Twice Daily - BID | Cohort A: ORMD-0801 Three Times Daily - TID | Cohort B:ORMD-0801, 8 mg Once Daily - QD | Cohort B: ORMD-0801 8 mg Twice Daily - BID | Cohort B: ORMD-0801 16 mg Once Daily - QD | Cohort B: ORMD-0801 16 mg Twice Daily - BID | Sub-Cohort A: Excipient Matched Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Asian | 0 | 0 | 2 | 1 | 0 | 0 | 1 | 2 | 0 | 6 |
| Native Hawaiian or Other Pacific Islander | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 4 |
| Black or African American | 11 | 7 | 8 | 8 | 3 | 4 | 1 | 1 | 3 | 46 |
| White | 69 | 59 | 57 | 58 | 12 | 11 | 16 | 11 | 17 | 310 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 2 | 0 | 0 | 0 | 2 | 0 | 1 | 0 | 6 |
| BMI(Kg/M^2) | Cohort A+Cohort B Combined: Matched Oral Capsule Placebo | Cohort A: ORMD-0801 Once Daily - QD | Cohort A: ORMD-0801 Twice Daily - BID | Cohort A: ORMD-0801 Three Times Daily - TID | Cohort B:ORMD-0801, 8 mg Once Daily - QD | Cohort B: ORMD-0801 8 mg Twice Daily - BID | Cohort B: ORMD-0801 16 mg Once Daily - QD | Cohort B: ORMD-0801 16 mg Twice Daily - BID | Sub-Cohort A: Excipient Matched Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 31.137 ± 4.7750 | 31.721 ± 4.9409 | 30.447 ± 4.7710 | 31.191 ± 4.0045 | 31.759 ± 4.4393 | 31.005 ± 5.0333 | 31.881 ± 6.0514 | 30.776 ± 5.4530 | 31.310 ± 5.5976 | 31.171 ± 4.7203 |
| HbA1c(percent HbA1c) | Cohort A+Cohort B Combined: Matched Oral Capsule Placebo | Cohort A: ORMD-0801 Once Daily - QD | Cohort A: ORMD-0801 Twice Daily - BID | Cohort A: ORMD-0801 Three Times Daily - TID | Cohort B:ORMD-0801, 8 mg Once Daily - QD | Cohort B: ORMD-0801 8 mg Twice Daily - BID | Cohort B: ORMD-0801 16 mg Once Daily - QD | Cohort B: ORMD-0801 16 mg Twice Daily - BID | Sub-Cohort A: Excipient Matched Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 9.46 ± 1.434 | 8.96 ± 1.281 | 9.36 ± 1.656 | 9.64 ± 1.578 | 9.83 ± 1.759 | 8.46 ± 1.104 | 8.96 ± 1.420 | 9.18 ± 1.687 | 8.93 ± 0.929 | 9.31 ± 1.512 |
| Diabetes Medications(Participants) | Cohort A+Cohort B Combined: Matched Oral Capsule Placebo | Cohort A: ORMD-0801 Once Daily - QD | Cohort A: ORMD-0801 Twice Daily - BID | Cohort A: ORMD-0801 Three Times Daily - TID | Cohort B:ORMD-0801, 8 mg Once Daily - QD | Cohort B: ORMD-0801 8 mg Twice Daily - BID | Cohort B: ORMD-0801 16 mg Once Daily - QD | Cohort B: ORMD-0801 16 mg Twice Daily - BID | Sub-Cohort A: Excipient Matched Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Metformin Alone | 22 | 20 | 20 | 12 | 6 | 5 | 7 | 5 | 6 | 103 |
| Metformin, No Sulfonylureas, but At Least 1 Other Medication | 13 | 10 | 8 | 12 | 1 | 0 | 1 | 2 | 1 | 48 |
| Metformin with Sulfonylureas Only | 33 | 30 | 26 | 33 | 7 | 7 | 8 | 3 | 4 | 151 |
| Metformin with Sulfonylureas and Other Medication(s) | 10 | 5 | 8 | 6 | 0 | 1 | 1 | 3 | 6 | 40 |
| Not on Metformin, But On 1 Other Medication | 4 | 4 | 3 | 4 | 1 | 2 | 0 | 1 | 1 | 20 |
| Not on Metformin, But On At Least 2 Other Medications | 0 | 0 | 3 | 2 | 0 | 2 | 1 | 1 | 2 | 11 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from May 2018 to primary completion in Oct 2019, 16 months.
Results were first posted in Nov 2022, 3 years after primary completion.
Of 194 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's 16 months is above that.
Counting every sponsor, half of 293 studies reached it within 15 months; a quarter within 11 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: ORMD-0801
Oramed, Ltd.